TG Therapeutics, Inc.
TGTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $5 | $6 | $4 |
| - Cash | – | $0 | $0 | $0 |
| + Debt | – | $0 | $0 | $0 |
| Enterprise Value | – | $5 | $6 | $4 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 14.6% | 16.8% | 11.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 82.6% | 86.6% | 87.1% | 85.8% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 20.2% | 26.7% | 10.2% | 30.1% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 241.7% | 20% | 4.2% | 21.6% |
| EPS Diluted | 2.428 | 0.17 | 0.031 | 0.15 |
| % Growth | 1,328.2% | 446.6% | -79.3% | – |
| Operating Cash Flow | – | $0 | -$0 | -$0 |
| Capital Expenditures | – | -$0 | -$0 | -$0 |
| Free Cash Flow | – | $0 | -$0 | -$0 |